Skip to evidence report

IPSC.mesodermal_primed: Studies — page 13

How association tiers are defined — cell–trait and gene–trait

SCREATE tier definitions supplied by the atlas curator. This methods note explains the prepared classifications; it does not recompute or change any report scores or tiers.

Cell–trait tiers

Cell–trait links
Identify cell types whose regulatory activity is associated with a trait’s genetic signal.
Required for Specific or Relevant
The ICE-CREAM score derived from the mean metacell Z score must be ≥ 5.39, with BOTH nominal and adjusted ICE-CREAM P values ≤ 0.05.
Specific (Tier 1)
Also meets all cell-set enrichment analysis (CSEA) criteria in at least one tested comparison: nominal P ≤ 0.05 AND adjusted P ≤ 0.05 AND normalized enrichment score (NES) ≥ 1, all in that comparison. This indicates that trait-associated activity is concentrated in this cell type relative to the tested background.
Relevant (Tier 2)
Meets the ICE-CREAM requirements but not the additional CSEA criteria. The cell type may share trait-associated activity with other cell types.
Interpretation and report values
CSEA is cell-set enrichment analysis, analogous to gene-set enrichment analysis but using sets of cells along a ranked list of ICE-CREAM scores. The eligibility score derived from the mean metacell Z score is not the displayed mean IC score. Do not infer a tier from the displayed mean, its descriptive Significance column, or a single CSEA summary value. Reports preserve prepared tiers; Other means an available association outside Specific/Relevant, and unavailable is not zero or proof of biological irrelevance.
Meta traits and individual traits
Use the prepared tier for the exact meta trait or individual trait. A meta trait’s Best child CSEA FDR is the lowest available child FDR, not a combined or meta-trait significance test. Its displayed mean child NES is descriptive, not a new CSEA test. These summaries must not be used to reconstruct or override the meta-trait tier.

Gene–trait priorities (variant–tCRE–gene evidence)

Variant–tCRE–gene links
Candidate variants connect to genes through overlapping promoters or distal transcribed cis-regulatory elements (tCREs) linked to gene promoters by the Activity-by-Contact (ABC) model.
Required genetic support
The variant belongs to a purity-passing SuSiE credible set OR qualifies for Borzoi rescue. Borzoi rescue requires BOTH a variant-causality score ≥ 0.3 AND linkage disequilibrium with the lead variant of r² ≥ 0.2.
Required cellular support
The overlapping promoter has positive tCRE activity OR the distal element has a passing cell-specific ABC link to the gene, in a Specific or Relevant cell subtype (L1S) or fine-grained state (L2). BOTH genetic and cellular support are required for High or Medium priority.
High priority
Among records meeting both minimum requirements, High requires a genetic score ≥ 0.5 AND a Layer 1 correlation > 0.3 between tCRE activity and the trait’s cellular profile across cell subtypes.
Medium priority
Meets both minimum requirements but not one or both additional High thresholds. The genetic score is the higher of the SuSiE posterior inclusion probability (PIP) and the Borzoi variant-causality score.
Same-record evidence and aggregation
Each priority requires genetic and cellular evidence supporting the SAME variant–tCRE–gene record. Do not combine thresholds or evidence from different records to create a qualifying link. A gene receives the highest priority observed among its supporting records. A tCRE summary uses supporting records for that exact tCRE, not every trait of its linked genes. Separately displayed aggregate scores do not relax the same-record rule.
Limits of interpretation
A priority is candidate-association evidence, not proof of a causal variant, causal gene, causal cell type or treatment efficacy. Missing evidence is unavailable, not zero. MAGMA −log10(P), displayed credibility scores, cellular-context scores and G/C tier codes must not be substituted for these eligibility tests; use the provided records and their documented fields.

State · 1,329 full-atlas cells · all tissues.

Marker genes and cell annotation · Open this population in Cell Browser →

ICE-CREAM (IC) is −log10(P) from a permutation test. An IC score of 3 corresponds to an unadjusted P value of 0.001; 5.5 is the multiple-testing-corrected significance threshold across all metacells. The Significance categories are Significant for IC > 5.5, Nominal for 3 ≤ IC ≤ 5.5, and Nonsignificant for IC < 3. These reports display mean IC scores across full-atlas populations, not the UMAP sample. The categories apply to the displayed scores: a cell-group mean or an average across individual traits is descriptive and is not itself a newly tested P value or a new multiple-testing correction. All scores are retained. Enrichment is not proof of causality or treatment efficacy.

Rows 12,001–12,313 of 12,313; ranked by score descending. Equal values use name/identifier order.

Studies ranked for IPSC.mesodermal_primed
#Trait / studyIndividual trait IDMean IC score
12001RNF5 levelsGCST904704888.39e-06
12002DCTN1/TRIAP1 ratioGCST903144348.38e-06
12003DAG1/PDGFB ratioGCST903143798.35e-06
12004Crohn's diseaseGCST904467938.31e-06
12005CD84/VASH1 ratioGCST903139208.26e-06
12006PTPRM/SELE ratioGCST903157538.18e-06
12007Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35)GCST903093698.15e-06
12008GZMA levelsGCST904694238.13e-06
12009FUT8/TNFSF12 ratioGCST903148948.04e-06
12010IL1R1/IL1RN ratioGCST903151587.98e-06
12011Total lipids in large HDL (UKB data field 23559)GCST902696567.93e-06
12012TIMP1 levelsGCST904708697.89e-06
12013Ulcerative colitis, NASFING000013907.86e-06
12014BPIFA2 levelsGCST904684617.75e-06
12015ANKRD54 levelsGCST904683117.69e-06
12016FCRLB levelsGCST904692107.65e-06
12017SELE levelsGCST904705667.64e-06
12018CD101 levelsGCST904685967.58e-06
12019CASP3/PDGFB ratioGCST903136387.52e-06
12020Liver iron contentGCST900166747.50e-06
12021DKK1/SDC4 ratioGCST903144797.48e-06
12022Total protein levelsGCST900259957.43e-06
12023Other (seronegative) rheumatoid arthritis, wideFING000009177.25e-06
12024DTYMK levelsGCST904690497.23e-06
12025DPP6 levelsGCST904690347.21e-06
12026GPC5 levelsGCST904693877.18e-06
12027PPM1B levelsGCST904702967.15e-06
12028CLEC4D/CLEC6A ratioGCST903141097.15e-06
12029PolyarthropathiesFING000011807.13e-06
12030SIGLEC6 levelsGCST904706347.03e-06
12031White blood cell countGCST900259857.02e-06
12032SIGLEC1 levelsGCST904706327.00e-06
12033ITGB1BP2/USP8 ratioGCST903152236.96e-06
12034LPCAT2 levelsGCST904697876.93e-06
12035ASAH1 levelsGCST904683736.89e-06
12036Neutrophil percentage of white cellsGCST0046336.89e-06
12037ALCAM/CNTN1 ratioGCST903132356.84e-06
12038TNFRSF14/TNFRSF1A ratioGCST903159356.84e-06
12039DCXR/KYNU ratioGCST903144386.82e-06
12040ACY3 levelsGCST904682136.72e-06
12041Lymphocyte percentage (UKB data field 30180)GCST904680836.61e-06
12042Rheumatoid arthritis (PheCode 714.1)GCST904762306.58e-06
12043CIAPIN1/VEGFC ratioGCST903140716.57e-06
12044THPO levelsGCST904708576.52e-06
12045TNF levelsGCST904709246.48e-06
12046EPHA1 levelsGCST904691296.44e-06
12047Lymphocyte percentage of white cellsGCST900023896.38e-06
12048ARSA/CD164 ratioGCST903133516.36e-06
12049MYLPF levelsGCST904699806.32e-06
12050SCARA5 levelsGCST904705336.27e-06
12051Phospholipids in large HDL (UKB data field 23560)GCST902696576.25e-06
12052HDL cholesterolGCST0007556.24e-06
12053FKBP4/SIRT2 ratioGCST903148416.23e-06
12054MEP1A levelsGCST904698876.22e-06
12055PTPRN2 levelsGCST904703856.16e-06
12056LPO levelsGCST904697896.08e-06
12057GBP1 levelsGCST904693116.08e-06
12058ITGB1/ITGB2 ratioGCST903152256.04e-06
12059FKBPL levelsGCST904692466.04e-06
12060BGLAP levelsGCST904684406.00e-06
12061Phospholipids in very large HDL (UKB data field 23553)GCST902696505.99e-06
12062Mucosal proctocolitisFING000008415.94e-06
12063CRELD2/HYOU1 ratioGCST903142555.86e-06
12064BIRC2/CD40LG ratioGCST903135175.83e-06
12065DPP6/NELL2 ratioGCST903145415.73e-06
12066Arachidoylcarnitine (C20) levelsGCST902001355.72e-06
12067PEAR1/PECAM1 ratioGCST903156415.71e-06
12068PEAR1/SNAP23 ratioGCST903156435.69e-06
12069CCL17/GRK5 ratioGCST903136875.67e-06
12070CXCL10 levelsGCST904689235.61e-06
12071FHIT/PRTFDC1 ratioGCST903148235.60e-06
12072AHNAK levelsGCST904682615.48e-06
12073Spondylopathies (FG)FING000013265.47e-06
12074RETN levelsGCST904704575.44e-06
12075CCN4 levelsGCST904685905.42e-06
12076TGFB1 levelsGCST904708435.42e-06
12077FCRL5/TNFRSF13B ratioGCST903148055.38e-06
12078PRSS53 levelsGCST904703445.28e-06
12079Basophil countGCST900259975.23e-06
12080Cholesterol to total lipids ratio in very large HDLGCST900930055.19e-06
12081Concentration of large HDL particlesGCST904978285.11e-06
12082Free cholesterol to total lipids in very large HDL percentage (UKB data field 23632)GCST902697294.97e-06
12083ARSA/GUSB ratioGCST903133554.96e-06
12084FOXO1/SNAP23 ratioGCST903148754.85e-06
12085SFRP2 levelsGCST902427274.74e-06
12086CLEC4D/MANSC1 ratioGCST903141124.66e-06
12087CRELD2/NUCB2 ratioGCST903142564.62e-06
12088Free thyroxine levels within normal range in pregnancyGCST904351964.59e-06
12089RSPO1 levelsGCST904705034.59e-06
12090Lymphocyte percentage | Blood countUKBB000004124.58e-06
12091ANGPT1/MPIG6B ratioGCST903132654.57e-06
12092APOBR levelsGCST904683344.54e-06
12093MET levelsGCST904698954.41e-06
12094FKBP4/FKBP5 ratioGCST903148384.39e-06
12095Severity of induration at injection site at the injection site after COVID-19 booster vaccinationGCST904544094.27e-06
12096Phospholipids to total lipids in very large HDL percentage (UKB data field 23629)GCST902697264.21e-06
12097PIGR levelsGCST904702324.20e-06
12098FKBP4/WWP2 ratioGCST903148424.19e-06
12099FUOM levelsGCST904692764.19e-06
12100HBEGF/SDC4 ratioGCST903150374.15e-06
12101CRTAM/TNFRSF9 ratioGCST903142804.12e-06
12102IL10 levelsGCST904695464.10e-06
12103PDAP1 levelsGCST904701794.03e-06
12104MAP4K5/STAMBP ratioGCST903153824.02e-06
12105CD74/TIMD4 ratioGCST903138963.95e-06
12106LTBP3 levelsGCST904698153.95e-06
12107CCL17/THPO ratioGCST903136893.77e-06
12108CD58/SIRPB1 ratioGCST903138553.73e-06
12109DLK1/PIK3IP1 ratioGCST903144923.73e-06
12110YARS1 levelsGCST904710873.72e-06
12111BLMH/SERPINE1 ratioGCST903135203.71e-06
12112PRSS27 levelsGCST904703423.66e-06
12113DIABLO/VSIR ratioGCST903144703.66e-06
12114DNER levelsGCST904690193.61e-06
12115BAMBI levelsGCST904684203.57e-06
12116CRYZL1 levelsGCST904688783.53e-06
12117Atopic dermatitisGCST900185643.42e-06
12118WFIKKN2 levelsGCST904710773.35e-06
12119NPHS1 levelsGCST904700703.34e-06
12120COX5B levelsGCST904688343.34e-06
12121GZMA/IL12A_IL12B ratioGCST903150093.32e-06
12122DNAJB14 levelsGCST904690113.27e-06
12123FCRL5/MZB1 ratioGCST903148043.27e-06
12124CIRBP levelsGCST904687563.26e-06
12125STIP1 levelsGCST904707643.24e-06
12126CHAC2 levelsGCST904687363.22e-06
12127Operative procedures - Unspecified diagnostic endoscopic examination of bladder | Summary OperationsUKBB000005903.17e-06
12128STIP1/TMSB10 ratioGCST903158903.14e-06
12129PPP2R2A levelsGCST906181223.11e-06
12130PRR4 levelsGCST904703383.09e-06
12131RGMB/TNFRSF21 ratioGCST903157723.05e-06
12132Malignant melanoma, excluding all cancers (controls excluding all cancers)FING000007503.05e-06
12133FCRL6/KLRD1 ratioGCST903148073.03e-06
12134Glomerular filtration rate (creatinine)GCST0033722.99e-06
12135ASRGL1 levelsGCST904683792.94e-06
12136FGR/LBR ratioGCST903148142.93e-06
12137IFNGR1/IL10RB ratioGCST903151272.93e-06
12138NID1/SORT1 ratioGCST903155422.92e-06
12139OLR1/OSM ratioGCST903155832.85e-06
12140CNPY4/MESD ratioGCST903141522.81e-06
12141COLEC12/TNFRSF1A ratioGCST903141872.81e-06
12142MAN1A2 levelsGCST904698432.80e-06
12143PIK3IP1/TNFRSF1B ratioGCST903156542.74e-06
12144KLRK1 levelsGCST904697132.57e-06
12145PLXNB3/SNAP23 ratioGCST903156932.56e-06
12146CRADD levelsGCST904688542.43e-06
12147ARSA levelsGCST904683682.40e-06
12148TACC3 levelsGCST904707972.40e-06
12149PIBF1 levelsGCST904702312.37e-06
12150STAT5B levelsGCST904707592.35e-06
12151Crohn's diseaseGCST904753182.35e-06
12152FGFBP3 levelsGCST904692322.35e-06
12153FUT8 levelsGCST904692812.30e-06
12154SLAMF1 levelsGCST902748352.29e-06
12155NUB1/SRPK2 ratioGCST903155732.28e-06
12156CX3CL1 levelsGCST902412042.22e-06
12157F9/FETUB ratioGCST903147462.13e-06
12158S100A11/S100A12 ratioGCST903157982.13e-06
12159Cream likingGCST900947462.07e-06
12160SCG3 levelsGCST904705392.05e-06
12161CCN2 levelsGCST904685882.05e-06
12162BTN2A1/SIGLEC1 ratioGCST903135482.00e-06
12163DIABLO/DOK2 ratioGCST903144641.98e-06
12164FCRL2 levelsGCST904692061.96e-06
12165Neutrophill percentage | Blood countUKBB000004981.95e-06
12166Tonsillectomy and adenotomyFING000013671.95e-06
12167Mean platelet (thrombocyte) volume | Blood countUKBB000004501.92e-06
12168Mean platelet thrombocyte volume (UKB data field 30100)GCST904680871.92e-06
12169Total lipids in very large HDL (UKB data field 23552)GCST902696491.89e-06
12170GlaucomaFING000005771.87e-06
12171CD74/NPDC1 ratioGCST903138951.84e-06
12172APP/NID1 ratioGCST903133261.82e-06
12173HNRNPUL1 levelsGCST904694701.80e-06
12174GALNT2 levelsGCST904692961.76e-06
12175GFRA1 levelsGCST904693281.75e-06
12176CD5L levelsGCST904686401.72e-06
12177DNAJB1 levelsGCST904690121.69e-06
12178Mean platelet volume during first trimester of pregnancyGCST903022291.67e-06
12179TG levelsGCST904708511.62e-06
12180C1QL2 levelsGCST904684871.58e-06
12181DNPH1/PDGFB ratioGCST903145271.57e-06
12182ADGRE1 levelsGCST904682361.56e-06
12183SF3B4/SIRT2 ratioGCST903158381.51e-06
12184Neutrophill percentage (UKB data field 30200)GCST904680931.49e-06
12185DTI autoptx L3 fmi tractGCST903852041.48e-06
12186PLXNA4/SRPK2 ratioGCST903156881.47e-06
12187PAMR1 levelsGCST904701551.46e-06
12188Aspartate aminotransferase levelsGCST900187241.45e-06
12189CLEC1B/PLXNA4 ratioGCST903141001.42e-06
12190Average diameter for HDL particlesGCST900928281.41e-06
12191TMSB10/TREML2 ratioGCST903159231.34e-06
12192Taking other prescription medications | MedicationUKBB000008131.33e-06
12193RBFOX3 levelsGCST904704321.33e-06
12194IL12B levelsGCST904695491.29e-06
12195EPHB6/VWC2 ratioGCST903146831.29e-06
12196Neutrophil percentage of white cellsGCST900023991.27e-06
12197HSPG2/PTGDS ratioGCST903150921.24e-06
12198POLR2F levelsGCST904702831.24e-06
12199DARS1/MAP4K5 ratioGCST903144041.23e-06
12200TNFRSF13B levelsGCST904709051.22e-06
12201PLXNA4/SPRY2 ratioGCST903156871.21e-06
12202Sphingomyelin_41:0_[M+H]1+ levelsGCST900603861.20e-06
12203Principal component-derived dietary pattern 33GCST901330381.19e-06
12204CD40LG/TRAF2 ratioGCST903138281.18e-06
12205TP53BP1 levelsGCST904709361.17e-06
12206NECTIN2/VSIR ratioGCST903155331.16e-06
12207Left hippocampal volume (tail)GCST902679511.14e-06
12208AMIGO2 levelsGCST904682921.08e-06
12209EPS8L2 levelsGCST904691381.06e-06
12210CD300E/EFNA4 ratioGCST903137971.05e-06
12211SELP levelsGCST904705691.02e-06
12212Suppurative and unspecified otitis mediaFING000013461.00e-06
12213SDC4/SEMA4D ratioGCST903158189.92e-07
12214ALCAM/ENPP2 ratioGCST903132369.75e-07
12215LGALS9/SIGLEC1 ratioGCST903153239.70e-07
12216ALB levelsGCST900259929.33e-07
12217DLL1/NOTCH1 ratioGCST903144988.79e-07
12218FOXO1/NUB1 ratioGCST903148748.73e-07
12219Enteropathic arthropathiesFING000005088.57e-07
12220SERPINB8 levelsGCST904705928.46e-07
12221CD55/PTGDS ratioGCST903138478.35e-07
12222APRT/EREG ratioGCST903133358.12e-07
12223NID1/TIMP3 ratioGCST903155437.94e-07
12224CCL22/TIMP3 ratioGCST903136937.82e-07
12225ALB levelsGCST904971087.66e-07
12226QPCT/RNASET2 ratioGCST903157587.54e-07
12227Spicy food likingGCST900948467.49e-07
12228DKK1/LGALS8 ratioGCST903144727.41e-07
12229MICB_MICA/TEK ratioGCST903154467.09e-07
12230HDL cholesterolGCST0022237.08e-07
12231Ulcerative colitis (strict definition, require KELA, min 2 HDR)FING000013887.03e-07
12232INPP1/NT5C3A ratioGCST903151777.02e-07
12233Platelet distribution width (UKB data field 30110)GCST904680976.78e-07
12234MZB1/TNFRSF13B ratioGCST903155096.66e-07
12235CES2 levelsGCST904687196.51e-07
12236CD8A levelsGCST904686556.42e-07
12237CCL11/CCL13 ratioGCST903136716.38e-07
12238CD302 levelsGCST904686246.26e-07
12239ACVRL1 levelsGCST904682116.17e-07
12240OSM levelsGCST904701335.88e-07
12241HSPB1/QDPR ratioGCST903150895.84e-07
12242LGALS4 levelsGCST904697625.82e-07
12243LY9 levelsGCST904698245.78e-07
12244Cholesterol in very large HDL (UKB data field 23554)GCST902696515.69e-07
12245LAT2/MANF ratioGCST903152775.44e-07
12246CD72 levelsGCST904686465.10e-07
12247CDH2/SSC4D ratioGCST903139515.07e-07
12248Concentration of very large HDL particles (UKB data field 23551)GCST902696484.76e-07
12249TNFRSF10B levelsGCST900120214.69e-07
12250Free cholesterol to total lipids ratio in very large HDLGCST900930094.57e-07
12251HSPB1/PLIN3 ratioGCST903150884.52e-07
12252ALB levelsUKBB000000194.49e-07
12253FABP1 levelsGCST904691734.45e-07
12254ALB levelsGCST904751034.42e-07
12255DLL1/TGFBR2 ratioGCST903144994.42e-07
12256SERPINE1 levelsGCST904705964.11e-07
12257ALB levelsGCST904751004.00e-07
12258DAG1/DBNL ratioGCST903143723.96e-07
12259Diseases of white blood cells (PheCode 288)GCST904758123.95e-07
12260NADK/PXN ratioGCST903155123.70e-07
12261SPINT2 levelsGCST904707283.68e-07
12262Thyroid cancer (PheCode 193)GCST904756003.67e-07
12263TRAF2/WWP2 ratioGCST903159433.63e-07
12264PDGFA/PRSS27 ratioGCST903156163.53e-07
12265COLEC12/NBL1 ratioGCST903141833.43e-07
12266SRPK2/VASH1 ratioGCST903158862.63e-07
12267CETN2/TDRKH ratioGCST903140312.55e-07
12268NME3 levelsGCST904700552.54e-07
12269ChalazionFING000002672.48e-07
12270GFRA2/IL12A_IL12B ratioGCST903149252.44e-07
12271CD99/KITLG ratioGCST903139242.35e-07
12272FYB1 levelsGCST904692842.27e-07
12273Total protein levelsGCST904681052.24e-07
12274SDC4/WWP2 ratioGCST903158212.23e-07
12275GZMA/TNFRSF4 ratioGCST903150132.16e-07
12276SIRT2 levelsGCST904706421.93e-07
12277DLL1/NECTIN4 ratioGCST903144971.87e-07
12278CLEC1B/GP1BA ratioGCST903140911.86e-07
12279L3HYPDH levelsGCST904697241.86e-07
12280TOP2B levelsGCST904709341.85e-07
12281NPDC1 levelsGCST904700691.82e-07
12282CCL4 levelsGCST904685831.56e-07
12283SRP14 levelsGCST904707421.49e-07
12284APLP1 levelsGCST904683301.34e-07
12285CSF3 levelsGCST904688861.33e-07
12286PDGFA levelsGCST904701881.26e-07
12287ITGA11 levelsGCST904696331.17e-07
12288Total protein levelsUKBB000008261.17e-07
12289CLEC4D levelsGCST904687731.15e-07
12290Ulcerative proctitisFING000013938.64e-08
12291ADA levelsGCST904682318.59e-08
12292LAYN/TNFRSF4 ratioGCST903152917.30e-08
12293ERBB2 levelsGCST904691396.31e-08
12294SCARA5/SCARF2 ratioGCST903158085.09e-08
12295TREML1 levelsGCST904709614.98e-08
12296PRL levelsGCST904703324.94e-08
12297IL12A or IL12B levelsGCST904695484.55e-08
12298PTP4A3 levelsGCST904703754.23e-08
12299PLXDC1 levelsGCST904702633.53e-08
12300CCL5/RARRES2 ratioGCST903137042.32e-08
12301S100A13 levelsGCST904705142.28e-08
12302PIK3IP1/TNFRSF1A ratioGCST903156532.16e-08
12303Cyst of kidney, acquired (PheCode 586.2)GCST904761331.12e-08
12304CPXM1 levelsGCST904688491.09e-08
12305Ankylosing spondylitisFING000000891.09e-08
12306ITGB1/REG1A ratioGCST903152283.79e-09
12307DTX3 levelsGCST904690482.50e-09
12308CDHR2/SSC4D ratioGCST903139652.49e-09
12309PLXNB2 levelsGCST902422992.47e-09
12310SELPLG levelsGCST904705682.28e-09
12311QPCT levelsGCST904704011.99e-09
12312TNFSF13 levelsGCST904709217.73e-10
12313IL18 levelsGCST904695673.35e-10